Reports not available

Anovulatory infertility in women unresponsive to clomiphene or clomiphene contraindicated Controlled ovarian hyperstimulation

Sensitivity reactions Multiple pregnancy Thrombo-embolism Acne injection site irritation Fatigue Ovarian enlargement or cysts GI upset Headache Varococele Intermittant bleeding Distention Gynaecomastia Weight gain in men

Pregnancy, Lactation Elderly Pitutary or hypothalamus tumors Vaginal bleeding( organic causes ) Abnormal uterine bleeding Sex hormone dependent, breast, ovarian or uterine tumors Ovarian cyst or enlargement associated with PCOD Effective response not obtainable in primary ovarian failure, reproductive organic disorders Incompatible with pregnancy Primary testicular failure Infertility not due to hypogonadotrophic hypgonadism ( in men ) Uncontrolled thyroid or adrenal dysfunction Intracranial lesions Special precautions- Do complete gynaecologicl and appropiate endocrinological exam, first Monitor for ovarian enlargement, hyperstimulation Multiple pregnancies Monitor serum analysis in men hypothyroidism , adrenocortical deficiency hyperprolactinaemia polycystic ovarian disease if ovaries are enlarged on last day of therapy or evidence of ovarian hyperstimulation syndrome OHSS occurs, do not give hCG discontinue if evidence of OHSS occurs (eg excessive number of ovarian follicles seen by serum estradiol levels or ultrasound, abnormal pain ) thromboembolic disorders

Anovulatory infertility in women unresponsive to clomiphene or clomiphene contraindicated Controlled ovarian hyperstimulation

Dosage-

Anovulation- initially 75 -150 iu daily by sc injection Monitor response Superovulation- usually 150 t0 225iu daliy by sc or 3 menstrual cycle usually 2 weeks after starting GnRH agonisttreatment Monitor rrsponse

Male infertility- 150 iu 3 times per week for 4 months along with HCG . Treatment may need to be extended to 18 months

Use contraindicated. Observe caution